Metabolic changes that allow Plasmodium falciparum artemisinin-resistant parasites to tolerate oxidative stress.

ABSTRACT: Artemisinin-based treatments (ACTs) are the first therapy currently used to treat malaria produced by Plasmodium falciparum. However, in recent years, increasing evidence shows that some strains of P. falciparum are less susceptible to ACT in the Southeast Asian region. A data reanalysis of several omics approaches currently available about parasites of P. falciparum that have some degree of resistance to ACT was carried out. The data used were from transcriptomics and metabolomics studies. One mitochondrial carrier of the parasite possibly involved in the mechanisms of tolerance to oxidative stress was modeled and subjected to molecular dockings with citrate and oxoglutarate. An increase in glutathione production was detected, changing the direction of the flux of met

SUBMITTER: Bonive-Boscan AD 

PROVIDER: S-EPMC11731681 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature